Residency · Residency · Chronic Pain Management

Prolotherapy and Perineural Injection Therapy with Dextrose

Introduction

Prolotherapy (proliferative therapy) uses hypertonic dextrose solutions, typically 12.5-25%, injected at ligament and tendon entheses to stimulate a healing inflammatory cascade in chronic musculoskeletal pain. Perineural injection therapy (PIT), also called neural prolotherapy, uses 5% dextrose in sterile water injected subcutaneously along peripheral nerve courses to treat neurogenic pain. Pioneered by George Hackett in the 1950s (prolotherapy) and John Lyftogt in the 2000s (PIT), these techniques have evolved from empirical practice to an expanding evidence base with multiple RCTs. Both approaches share a favorable safety profile -- no local anesthetic systemic toxicity, no myotoxicity, no steroid-related tissue effects -- making them attractive for repeated treatment series.

Prolotherapy: Hypertonic Dextrose for Musculoskeletal Pain

Mechanism of Action

Hypertonic dextrose (12.5-25%) causes osmotic cellular stress, producing local cellular dehydration and micro-damage at the injection site. This triggers a controlled inflammatory cascade: neutrophil and macrophage recruitment, growth factor release (PDGF, TGF-beta, FGF, IGF-1), fibroblast proliferation, and collagen deposition. The net effect is strengthening and tightening of chronically lax or degenerated ligaments and tendons. A secondary analgesic effect comes from resolution of nociceptive input originating from incompetent stabilizing structures.

Indications with Evidence

Knee osteoarthritis has the strongest evidence. Multiple RCTs, notably by Rabago and colleagues, demonstrate significant and sustained improvement in pain, function, and stiffness at one year compared to saline and exercise controls. Lateral epicondylitis (tennis elbow) has RCT support showing superiority over watchful waiting and comparable or superior outcomes to corticosteroid at long-term follow-up, since steroids show early benefit but tend to rebound. Chronic low back pain with suspected ligamentous insufficiency has mixed evidence, with the best results seen when prolotherapy is combined with co-interventions such as exercise and spinal manipulation. Achilles tendinopathy responds to peritendinous injection (not intratendinous), with growing pilot data. Sacroiliac joint instability and ligamentous laxity have clinical series showing benefit in hypermobility-related SI pain. Rotator cuff tendinopathy and partial tears have emerging evidence, particularly for glenohumeral and acromioclavicular joint instability.

Technique

The typical concentration is 12.5-25% dextrose, with 15-20% most commonly used for tendons and ligaments and 25% for joint injections. The solution is prepared by mixing 50% dextrose stock solution with 1% lidocaine and/or sterile water to achieve the target concentration. Injection targets are fibro-osseous junctions (entheses), joint lines, and areas of ligament or tendon degeneration. Volumes of 0.5-1 mL are used per enthesis and 3-5 mL for intra-articular injections. A typical course involves 3-6 sessions at 2-4 week intervals, with reassessment after 3 sessions. Superficial structures can be treated with palpation guidance, while deeper targets (SI joint, hip, spine) require ultrasound or fluoroscopy.

Contrast with Corticosteroid Injection

Prolotherapy and corticosteroid injection work through fundamentally opposite mechanisms. Prolotherapy is pro-inflammatory and regenerative, promoting collagen synthesis and tissue strengthening, while corticosteroid is anti-inflammatory and suppressive, causing collagen degradation and tissue weakening. Prolotherapy is safe for peritendinous use and is designed for repeated dosing (series of 3-6), whereas corticosteroids carry tendon rupture risk and should be limited to 3-4 injections per year. Prolotherapy has a gradual onset (weeks to months) but potentially long-lasting structural effects, while corticosteroids provide rapid relief (days) that is typically temporary (weeks to months). For diabetic patients, prolotherapy has minimal glycemic impact at injection volumes, whereas corticosteroid injection causes significant hyperglycemia.

<image>Comparative illustration of prolotherapy mechanism of action at a tendon enthesis. Left panel (Before Treatment): cross-section of a chronically degenerated tendon-bone junction showing disorganized collagen fibers, micro-tears, neovascularization, and sparse fibroblasts with pain nerve fibers labeled. Center panel (Prolotherapy Injection): a needle depositing hypertonic dextrose solution at the enthesis, with an inset showing the cellular cascade — osmotic stress causing local cell lysis, neutrophil recruitment, macrophage activation, and growth factor release (PDGF, TGF-beta, IGF-1 labeled). Right panel (After Treatment Series): organized parallel collagen fibers, increased fibroblast density, and restored tendon-bone architecture. Timeline at bottom showing "3-6 sessions over 3-6 months." Clean medical illustration with histological detail.</image>

Perineural Injection Therapy (PIT) with 5% Dextrose

Background and Rationale

John Lyftogt observed that subcutaneous injection of 5% dextrose along the course of painful peripheral nerves produced sustained analgesic effects without the risks of local anesthetics or steroids. PIT is distinct from classic prolotherapy in several important ways: it uses isotonic to mildly hypertonic (5%) dextrose, targets nerves rather than connective tissue, and does not rely on an inflammatory mechanism.

Proposed Mechanisms

The leading proposed mechanism involves TRPV1 receptor modulation. Sensitized peptidergic C-fibers overexpress TRPV1 (transient receptor potential vanilloid 1), which drives neurogenic inflammation through substance P and CGRP release. Glucose appears to downregulate TRPV1 activity, reducing peripheral sensitization. A second hypothesis involves correction of perineural glucopenia: chronically irritated nerves may develop a local glucose deficit from high metabolic demand, and 5% dextrose may restore axonal energy metabolism. Mechanical effects also contribute, as subcutaneous hydrodissection and needling interrupt adhesions and perineural fibrosis. A mild osmotic effect may play a role as well, since 5% dextrose is slightly hypertonic relative to the interstitium (278 versus approximately 275 mOsm/L), potentially modulating the local neural environment.

Advantages Over Local Anesthetics

PIT with 5% dextrose offers several safety advantages over local anesthetics. It carries no myotoxicity, which is critical for repeated injections into muscle or near tendons. There is no LAST risk -- no cardiac, neurologic, or systemic toxicity at any clinically used volume. There is no proprioceptive or motor impairment, so patients can immediately resume functional activities after injection. It is diabetic-safe, since 10 mL of 5% dextrose contains only 0.5 g of glucose, producing a negligible systemic glycemic impact. The treatment is freely repeatable, administered weekly to biweekly without cumulative tissue harm. And unlike steroid adjuvants, dextrose does not confound subsequent diagnostic blocks.

Indications with Clinical Evidence

The strongest evidence supports PIT for carpal tunnel syndrome (CTS). Multiple RCTs (Wu et al., 2017; Lai et al., 2020) demonstrate non-inferiority or superiority to corticosteroid injection at 6 months, with sustained improvement in nerve cross-sectional area on ultrasound and without the tissue-thinning concerns of steroids. Lateral epicondylitis also has RCT support, with perineural dextrose around the posterior interosseous nerve branch producing sustained improvement.

Growing evidence supports PIT for plantar fasciitis (perineural injection along the medial calcaneal and inferior calcaneal nerves), Achilles tendinopathy (peritendinous and perineural along the sural nerve), occipital neuralgia and chronic migraine (perineural along the GON/LON course, which is particularly attractive for patients requiring repeated treatments), chronic neck and back myofascial pain (with comparable short-term and sometimes superior medium-term outcomes versus lidocaine TPIs in comparative studies), and knee osteoarthritis (both intra-articular dextrose at prolotherapy concentrations and perineural genicular dextrose, with the Rabago et al. RCT showing sustained benefit at one year versus saline).

Emerging pilot data exist for cubital tunnel syndrome, meralgia paresthetica, post-surgical neuropathic pain, and chronic pelvic pain (pudendal neuralgia).

<image>Anatomical illustration of perineural injection therapy (PIT) technique for the upper extremity. Main panel: anterior view of the forearm and wrist showing the median nerve course through the carpal tunnel, with 4-5 injection sites marked along the nerve path from mid-forearm to wrist crease. Each site shows a 27-gauge needle inserted subcutaneously at a shallow angle depositing 0.5-1 mL of 5% dextrose (colored in pale yellow) in the perineural space. Ultrasound inset: transverse sonographic image of the carpal tunnel showing the median nerve (hyperechoic oval) with a needle tip approaching from the ulnar side and dextrose hydrodissecting around the nerve (anechoic fluid halo). Bottom comparison panel: "Before PIT" ultrasound showing enlarged, hypoechoic (swollen) median nerve with cross-sectional area labeled, vs. "After 3-session PIT series" showing normalized nerve size and echogenicity. Clean medical illustration with labeled anatomical structures.</image>

Technique Principles

The solution is 5% dextrose in sterile water -- not normal saline, as saline dilution falls outside studied protocols and may reduce efficacy. Volumes of 0.5-2 mL are used per perineural site, with larger volumes (3-5 mL) for hydrodissection of entrapped nerves under ultrasound. Needle gauge is 27-30, with lengths of 0.5-1.5 inches depending on depth. Injection depth is subcutaneous, along the anatomic course of the affected nerve, guided by tender points -- what Lyftogt called "pain points," areas of maximal tenderness along the nerve trajectory. Palpation guidance is sufficient for superficial nerves (GON, LON, superficial radial, sural), while ultrasound is used for deeper structures (median nerve at the carpal tunnel, posterior interosseous nerve, pudendal nerve). A typical treatment series involves 3-6 sessions at 1-2 week intervals, though some patients respond after just 1-2 sessions while others require a full course. Some clinicians mix small amounts of lidocaine (0.5%) with 5% dextrose for patient comfort during injection, and outcomes appear comparable in the heterogeneous literature.

Side Effects and Safety

Post-injection soreness is transient (24-48 hours) and occurs in a minority of patients, generally milder than post-lidocaine TPI soreness. Mild bruising and vasovagal episodes can occur as with any injection procedure. There is no systemic toxicity at clinical doses and no tissue degradation -- no fat atrophy, skin depigmentation, or tendon weakening -- so dextrose can be safely injected near tendons. Infection risk is equivalent to any sterile injection procedure.

Practical Comparison: Lidocaine vs Steroid vs 5% Dextrose

Documentation and Procedural Standards

Pre-Procedure

Before each procedure, confirm the indication, target nerve or structure, laterality, allergies, and anticoagulation status. Informed consent should address post-injection soreness, bruising, infection risk, vasovagal episodes, and the expected treatment course (a series of 3-6 sessions). For PIT specifically, explain that benefit is typically cumulative over a treatment series, not an immediate single-session cure.

Documentation Per Session

Each session should document the indication and prior treatment response, the specific nerve, muscle, or enthesis targeted (including side and level), the drug, concentration, total volume, and number of injection sites, needle gauge, depth, and use of ultrasound guidance, the immediate response (pain VAS pre- and post-injection and any adverse events), and the plan including rehabilitation activities, interval to next session, and criteria for continuing versus concluding the series.

<image>Side-by-side clinical comparison infographic of three injection approaches for chronic pain. Three columns labeled "Lidocaine TPI," "Corticosteroid + LA," and "5% Dextrose PIT." Each column shows: (1) a syringe icon with the solution color-coded (clear for lidocaine, white suspension for steroid, pale yellow for dextrose), (2) mechanism of action icons (sodium channel for lidocaine, anti-inflammatory symbol for steroid, TRPV1 receptor modulation for dextrose), (3) safety profile radar chart comparing myotoxicity, LAST risk, tissue atrophy, repeatability, and systemic effects (green = favorable, red = concern), (4) typical treatment course timeline (single session vs. limited series vs. 3-6 session series), and (5) best clinical scenarios listed as bullet points. Bottom panel: a Venn diagram showing overlap conditions where combined approaches are used (e.g., lidocaine + dextrose for comfort during PIT). Clean, modern medical education infographic style.</image>

Clinical Pearls

Prolotherapy (hypertonic dextrose 12.5-25%) and PIT (5% dextrose) are distinct techniques with different mechanisms -- prolotherapy stimulates connective tissue repair via controlled inflammation, while PIT modulates neurogenic pain via TRPV1 downregulation. The strongest evidence for PIT is in carpal tunnel syndrome, where 5% dextrose perineural injection has shown non-inferiority or superiority to corticosteroid at 6 months without tissue-thinning side effects. The 5% dextrose must be mixed in sterile water, not saline -- saline dilutions fall outside studied protocols and may reduce efficacy. PIT is particularly valuable when repeated treatments are needed: no LAST risk, no myotoxicity, no motor or proprioceptive impairment, and safe in diabetic patients. Prolotherapy for knee osteoarthritis has the strongest RCT evidence among musculoskeletal indications, with demonstrated benefits sustained at one year. Both prolotherapy and PIT work best as part of an integrated program with concurrent rehabilitation -- they are not standalone cures. Always distinguish between prolotherapy (structural regeneration of connective tissue) and PIT (neural pain modulation) when discussing treatment rationale with patients and in documentation.

References

• Rabago D, Patterson JJ, Mundt M, et al. Dextrose Prolotherapy for Knee Osteoarthritis: A Randomized Controlled Trial. Ann Fam Med. 2013;11(3):229-237.
• Wu YT, Ho TY, Chou YC, et al. Six-Month Efficacy of Perineural Dextrose for Carpal Tunnel Syndrome: A Prospective, Randomized, Double-Blind, Controlled Trial. Mayo Clin Proc. 2017;92(8):1179-1189.
• Reeves KD, Sit RWS, Rabago D. Dextrose Prolotherapy: A Narrative Review of Basic Science, Clinical Research, and Best Treatment Recommendations. Phys Med Rehabil Clin N Am. 2016;27(4):783-823.
• Lyftogt J. Subcutaneous Prolotherapy Treatment of Refractory Knee, Shoulder, and Lateral Elbow Pain. Australas Musculoskelet Med. 2007;12(2):110-112.

Read this lecture as Markdown